pembrolizumab/quavonlimab (MK-1308A) coformulation
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for pembrolizumab/quavonlimab (MK-1308A) coformulation, covering 2026-06-23 to 2026-06-23. Get the full timeline:
Most recent: Clinical Trial Results: Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) [Phase 2]